Northern Trust Corp Boosts Stake in Xencor, Inc. (NASDAQ:XNCR)

Northern Trust Corp lifted its holdings in Xencor, Inc. (NASDAQ:XNCR) by 19.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 747,152 shares of the biopharmaceutical company’s stock after purchasing an additional 120,655 shares during the quarter. Northern Trust Corp’s holdings in Xencor were worth $17,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sterling Capital Management LLC increased its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. KBC Group NV increased its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 813 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,337 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Xencor by 22.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock valued at $162,000 after acquiring an additional 1,282 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Xencor by 132.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 4,482 shares during the last quarter.

Xencor Price Performance

Shares of Xencor stock opened at $8.14 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock’s fifty day moving average is $10.40 and its 200 day moving average is $17.39. The stock has a market cap of $579.18 million, a P/E ratio of -2.54 and a beta of 0.99. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor’s revenue was up 104.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.11) earnings per share. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on XNCR shares. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company reduced their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Barclays reduced their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. William Blair initiated coverage on Xencor in a report on Monday, April 21st. They issued an “outperform” rating on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares of the company’s stock, valued at $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.76% of the company’s stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.